Baseline | During RT | Follow-up | ||||||
---|---|---|---|---|---|---|---|---|
1st yeara | 2nd yeara | 3rd-5th yeara | ||||||
12wa | 6 ma | 9 ma | 12 ma | every 4 m | every 6 m | |||
Standard of care: | ||||||||
Physical examination | x | x | x | x | x | x | x | x |
Flexible endoscopy | x | x | x | x | x | x | x | |
Toxicity | x | x | x | x | x | x | x | x |
QoL-questionnaire | x | x | x | x | x | until 18th montha | ||
US-FNAC | x | x | x | x | x | when indicated | ||
CT or MRIb | x | x | when indicated | |||||
FDG-PET | x | when indicated | ||||||
Investigation under anesthesia | x | when indicated | ||||||
RT planning CT | x | |||||||
Extra in SUSPECT-2: | ||||||||
Signed informed consent | x | |||||||
Tracer injection and SPECT/CT | x | |||||||
Contralateral SNP | only when contralateral drainage is visualized on SPECT/CT |